Skip to content

Insulin Loaded Orally Dissolved Films (Insulin-ODF)

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01446120
Enrollment
7
Registered
2011-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2011-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Keywords

this is phase one study. The study population are healthy volunteers.

Brief summary

This study is assessing the pharmacokinetics efficacy and of Insulin loaded Orally Dissolved Films (insulin-ODF) treatment. The Insulin-ODF is attached to the inner tissue of the chick (buccal) , Releasing the insulin to the circulation, while the film is dissolved.. Primary endpoint: 1. The Cmax (Maximum Concentration of insulin in mg). 2. Tmax (the time to Cmax in minutes) 3. AUC (Area Under the Curve) of blood insulin levels during six hours of the trial. Secondary endpoints: 1. The glucose and C-peptide levels during six hours of the trial. (mg) 2. The safety of the treatment in a descriptive manner by recording all adverse events in the study population. Methods Seven healthy volunteers will be randomly assigned to one of the following groups: A. Insulin-ODF following treatment group; Or B. commercial NPH Insulin treatment. The study is designed a crossover, in which each group is treated 3-7 days of washout. The volunteer subjects will arrive to the clinic after eight hours fasting. Each subject will be examined by a physician, evaluating the elegibilities to the trial (i.e. inclusion and exclusion criteria). An I.V catheter will be administrated assessing the Glucose, Insulin and C-peptide levels, ten minutes and five minutes before injecting the NPH Insulin or the Insulin-ODF. Blood Insulin and glucose levels will be evaluated at baseline, and after the following time points: 15,30,60,90,120,150,180,210,240,270,300,330,360 minutes. C-peptide levels will be evaluated at baseline and after the following time points: 60,120,240, 360 minutes.

Interventions

DRUGNPH-Insulin Injection
DRUGInsulin loaded Orally Dissolved Films (insulin-ODF

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

1. Signed Informed Consent. 2. 18.5\<BMI\<30

Exclusion criteria

1. Smokers. 2. Known mouth cavity, gums or gastrointestinal disease.

Design outcomes

Primary

MeasureTime frameDescription
Blood InsulinTo assess the Cmax , Tmax and AUC (Area Under the Curve) of blood insulin level during six hours of the trial.

Secondary

MeasureTime frameDescription
glucose and C-peptide levelsEvaluating the glucose and C-peptide levels during six hours of the trial.
hypoglycemia and irritation.All the examinations will be done in the presence of a physician along with a medical assistant. Hypoglycemia and irritation are the main adverse event that we anticipate in this study. In any such event the proper reporting and treatment will be administrated, while these subjects will be followed up for a further 1 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026